Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel J Canter

Showing results (71-80 of 73) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 73 results.
The Journal of Urology|December 3, 2014
Surgical Apgar Score predicts an increased risk of major complications and death after renal mass excisionTimothy Ito, Philip H Abbosh, Reza Mehrazin, et al.
The New England Journal of Medicine|November 26, 2024
Standard or Extended Lymphadenectomy for Muscle-Invasive Bladder CancerSeth P Lerner, Catherine Tangen, Robert S Svatek, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 24, 2017
Intravesical rAd-IFNα/Syn3 for Patients With High-Grade, Bacillus Calmette-Guerin-Refractory or Relapsed Non-Muscle-Invasive Bladder Cancer: A Phase II Randomized StudyNeal D Shore, Stephen A Boorjian, Daniel J Canter, et al.
Pageof 8

Showing results (71-80 of 73) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 73 results.
The Journal of Urology|December 3, 2014
Surgical Apgar Score predicts an increased risk of major complications and death after renal mass excisionTimothy Ito, Philip H Abbosh, Reza Mehrazin, et al.
The New England Journal of Medicine|November 26, 2024
Standard or Extended Lymphadenectomy for Muscle-Invasive Bladder CancerSeth P Lerner, Catherine Tangen, Robert S Svatek, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 24, 2017
Intravesical rAd-IFNα/Syn3 for Patients With High-Grade, Bacillus Calmette-Guerin-Refractory or Relapsed Non-Muscle-Invasive Bladder Cancer: A Phase II Randomized StudyNeal D Shore, Stephen A Boorjian, Daniel J Canter, et al.
Pageof 8